GHK-Cu: the monograph

GHK-Cu is a copper complex of the tripeptide glycyl-L-histidyl-L-lysine, a fragment found in human plasma since it was first isolated in 1973 ^12,8. The free peptide weighs 340.38 Da; the 1:1 copper complex most products intend is recorded in PubChem at 401.91 Da, though several distinct complex records share the common name ^8,9.

One name covers three different products in 2026. On cosmetics shelves it is copper tripeptide-1, an ingredient in serums and creams that the law classifies as a cosmetic ^10,4. From compounding pharmacies it is a non-injectable drug ingredient allowed under an interim FDA policy still under evaluation ¹. From research-chemical websites it is a vial of injectable powder that FDA has flagged for safety concerns and that no human trial has ever tested ^2,53.

No FDA-approved drug contains GHK-Cu in any form: a Drugs@FDA ingredient query returns no matches ⁵. This page keeps the three tiers separate on every table, because the evidence for each is different in kind.

The fact chips on this page carry their evidence grade and claim id. The three status chips are the page's spine: cosmetic tier, cosmetics-law only; compounded non-injectable tier, interim Category 1 under evaluation; injectable tier, research-only with an FDA safety-risks listing ^4,1,2.

The serum: copper tripeptide-1 in cosmetic formulations. Cosmetics get no FDA premarket approval and may not make drug claims ⁴. The CIR expert panel reviewed the ingredient and concluded it is safe as used, while recording that surveyed use concentrations were typically under 10 ppm ¹⁰. The human evidence behind serum marketing is small, cosmetic-graded and heavily tied to the originating researcher's commercial lineage ^42,51.

The compounded product: non-injectable GHK-Cu (creams, topical preparations and other non-injectable routes) can be compounded under FDA's interim 503A policy because the substance sits in Category 1, under evaluation ¹. Category 1 is not an approval and not a finding of safety or effectiveness; it is a holding pattern while FDA evaluates the substance, with a PCAC consultation announced for before the end of February 2027 ¹.

The vial: injectable GHK-Cu is sold as a research chemical. FDA's safety-risks page flags immunogenicity risk from aggregation and peptide-related impurities and notes limited human data ². No registered trial and no published human study has ever tested injected GHK-Cu ^6,53. An April 2026 preprint analyzing 6,441 consumer research-peptide samples, GHK-Cu among the fourteen compounds, found 41.6% to 71.1% failing basic quality criteria and endotoxin in 15% ¹¹.

Same molecule, three legal objects, three evidence bases. Everything below is labeled by tier so the strong preclinical science cannot be silently spent on behalf of whichever product is being sold.

There has never been an FDA-approved GHK-Cu drug ⁵. The regulatory map has three lanes.

Cosmetic lane: copper peptide serums and creams are cosmetics. FDA states that cosmetic products and ingredients, other than color additives, do not need FDA approval before they go on the market; the tradeoff is that cosmetics may not make disease-treatment claims ⁴.

Compounding lane: GHK-Cu was nominated for the 503A bulks list, which would let state-licensed pharmacies compound with it. On April 22, 2026 FDA removed GHK-Cu from Category 1 because its nominations were withdrawn. On May 5, 2026 one nominator clarified that it had meant to withdraw only the injectable route, and FDA restored the entry as "GHK-Cu (except for injectable routes of administration)" ¹. FDA has announced it intends to consult the Pharmacy Compounding Advisory Committee before the end of February 2027 ¹. Until that process ends, compounded non-injectable GHK-Cu exists under an interim enforcement policy, not an approval ³.

Injectable lane: injectable GHK-Cu lost its nomination and appears on FDA's safety-risks page with the immunogenicity and impurity language quoted in the warning box ². The only GHK-Cu drug trial registered anywhere is topical, a phase 2 wound-gel study now recruiting ⁷.

GHK began as a 1973 observation that a tripeptide in human serum changed how liver cells behaved in culture ¹². Its copper affinity and the wound-repair hypothesis came later from the same research lineage, which eventually commercialized copper peptide skincare; that lineage authored most of the reviews the market quotes ^44,41.

The famous age-decline figures, about 200 ng/mL of plasma GHK at age 20 falling to about 80 ng/mL by 60, trace to that early lineage and are restated in a 2020 review ⁴⁵. The only recent measured values we found are from a 2023 COPD study: 70.27 ng/mL in patients, 133.0 ng/mL in age-paired healthy adults ³⁴. The healthy-elderly mean of 133 does not match the 80 figure. We show both because neither settles the question; a modern population study of plasma GHK by age does not exist.

The tissue-remodeling biology is real and mostly preclinical. In fibroblast culture, GHK-Cu stimulated collagen synthesis at picomolar to nanomolar concentrations ¹³. Injected into rat wound chambers, it raised collagen, glycosaminoglycan, protein and DNA content concentration-dependently while a control tripeptide did nothing ¹⁴. It modulates matrix turnover in both directions, raising MMP-2 alongside its inhibitors TIMP-1 and TIMP-2 ¹⁵.

Two details complicate the marketing story. First, in the MMP-2 assay the effect was reproduced by copper ions alone and not by copper-free GHK, so at least part of the biology is copper delivery rather than peptide signaling ¹⁵. Second, the most striking modern mechanism result, a 127-gene emphysema signature that GHK opposed in a computational screen, used copper-free GHK on lung fibroblasts in vitro and has no clinical follow-up ¹⁸.

Keratinocyte work adds integrin, PCNA and p63 increases in skin-equivalent models ¹⁷, and irradiated human fibroblasts recovered growth rates with GHK-Cu exposure ¹⁶. The broad remodeling framework is articulated most completely in reviews from the originating researcher, a commercial interest we flag wherever they are cited ^41,43.

Our study table lists every row with species, route, tier and grade, because those columns carry the entire honest story: strong, repeated preclinical remodeling effects; a handful of small human studies at the cosmetic and wound tiers, one industry-run and positive, one independent and objective-null; rodent-only systemic data; and nothing human behind the vials ^51,53.

The publication-type census is the sharpest single fact: exactly one randomized controlled trial is tagged to GHK-Cu in the indexed literature, and its objective endpoints were null ^51,25. Independent 2025 reviews call the ingredient promising while conceding the published effectiveness and permeability information is insufficient ^47,46.

What exists at the cosmetic tier: in vitro and ex vivo collagen work, including a 2023 study where GHK-Cu with hyaluronic acid raised collagen IV 25.4-fold in cells and 2.03-fold in ex vivo skin, a combination result ¹⁹; and one randomized human study, the 2006 CO2-laser trial, in which GHK-Cu products produced no objective benefit on erythema, wrinkles or skin quality in 13 evaluable patients, while patient satisfaction favored them ²⁵.

What does not exist: any randomized monotherapy trial of a GHK-Cu serum on wrinkles, firmness or photoaging ⁵². The facial-improvement studies the market quotes are conference-era industry reports summarized in reviews by the originating researcher and never indexed as papers ^42,51. A 2025 methods review states plainly that published permeability and effectiveness information for GHK-Cu products is insufficient ⁴⁶.

The CIR panel's safety conclusion is genuine reassurance on tolerability as used, and it came with a number worth staring at: surveyed use concentrations were typically under 10 ppm, orders of magnitude below the percent-level figures on marketing pages ¹⁰.

The strongest human evidence GHK-Cu ever produced is the 1994 diabetic foot ulcer trial: multicenter, randomized, evaluator-blinded, placebo-controlled, run on top of aggressive standardized wound care. Median ulcer closure was 98.5% with GHK-Cu gel vs 60.8% with vehicle, closure ran about three times faster, large ulcers closed 89.2% vs a 10.3% worsening on vehicle, and infections were 7% vs 34% ²⁴. A scientist from ProCyte, the sponsor developing the gel, is a co-author, and the program never produced an approved product: no GHK-Cu wound drug exists today ⁵.

The animal record around it is split. Rabbit open wounds closed faster than controls and zinc oxide ²¹. Mouse scald burns improved with liposome-encapsulated GHK-Cu, which notably beat plain GHK-Cu, the form most products contain ²³. And in irradiated rat flaps, ten days of topical GHK-Cu gel changed nothing measurable ²². A recruiting phase 2 topical wound-gel trial may eventually update this section ⁷.

Check the compound column before believing a copper peptide hair claim. The most-quoted paper, 2007, stimulated human hair follicles ex vivo with AHK-Cu, alanyl-histidyl-lysine copper, a different peptide ²⁷. The 1993 rodent result used PC1031, a ProCyte copper binding peptide, on fuzzy rats ²⁰. The one randomized human trial in this area tested ALAVAX, 5-aminolevulinic acid complexed with copper-free GHK: hair counts rose against placebo over six months, hair length and thickness did not change, and no copper was involved ²⁶.

A 2025 report describes hair regrowth using tattoo-delivered minoxidil plus dutasteride plus copper peptides, a three-drug cocktail in which no copper peptide effect can be isolated, and it carries no indexed abstract ²⁸. Net: there is no randomized human trial of GHK-Cu itself for hair loss. Anyone selling GHK-Cu for hair on the strength of these papers is borrowing evidence from different molecules and mixtures.

Injected or systemic GHK-Cu has a real and growing animal literature, almost all of it from lung-disease models: LPS acute lung injury ²⁹, bleomycin fibrosis with intraperitoneal dosing ³⁰, cigarette-smoke emphysema ³¹, and silicosis, where a molecular target, peroxiredoxin 6, was identified ³². A COPD muscle study added the only human blood data: plasma GHK ran lower in patients than controls, alongside preclinical rescue experiments ³⁴.

Outside the lung: weekly intra-articular GHK-Cu improved rat ACL graft metrics at 6 weeks and the benefit disappeared by 12 weeks once injections stopped, the authors' own word being transiently ³³. Injected copper-free GHK prevented sleep-deprivation learning impairment in aging mice ³⁵. And in 2026, GHK-Cu extended lifespan in C. elegans, a roundworm ³⁶.

That worm study is the entire whole-organism longevity evidence. Every systemic claim on a peptide-vial site rests on this animal base, because the human injectable record is empty ⁵³.

Registered trials of injectable GHK-Cu: zero. The ClinicalTrials.gov census returns three GHK-Cu records, a cosmetic facial-device study, a topical wound-gel phase 2 trial, and a wellness-patch study, none injectable ⁶. Published human studies of injected GHK-Cu: zero ⁵³. Human pharmacokinetics of injected GHK-Cu: zero studies ⁵³.

What does exist for the vial tier is a quality problem: an April 2026 preprint analyzing 6,441 consumer research-peptide samples across fourteen compounds including GHK-Cu found 41.6% to 71.1% failing basic quality criteria and measurable endotoxin in 15%, findings that sit directly beside FDA's aggregation-and-impurity warning ^11,2. We publish no injectable dosing content because there is nothing honest to compute it from.

Is copper peptide skincare safe to use? The CIR expert panel concluded tripeptide-1 and copper tripeptide-1 are safe in the present practices of use and concentration, based partly on surveyed concentrations under 10 ppm and negative safety test data ¹⁰. The 2006 randomized laser study reported no between-group safety signal ²⁵.

Is compounded non-injectable GHK-Cu safe? Unknown in the FDA sense: Category 1 means under evaluation, and no product has passed an FDA safety review ¹.

Is injectable GHK-Cu safe? FDA's stated position is that compounded injectable GHK-Cu may pose immunogenicity risk from aggregation and peptide-related impurities, with limited human data to inform safety ². No human trial exists to characterize adverse effects, which is not evidence of safety; it is the absence of the study that would tell you ⁵³.

There is no drug label to quote, so the side-effect record is thin by construction. In the diabetic ulcer trial the treated group had fewer infections than vehicle, 7% vs 34% ²⁴. In the laser study, groups did not differ on tolerability-relevant objective measures ²⁵. The CIR review found the negative safety test data adequate at cosmetic concentrations ¹⁰.

For the injectable tier there is no human adverse-event dataset at all; FDA's impurity and immunogenicity language is the only authoritative safety statement in existence ².

Cosmetic tier: a serum marketed with acne, rosacea, hair-loss or any other disease-treatment claims is making drug claims without a drug approval ⁴.

Compounded tier: interim Category 1 status can change; FDA's PCAC consultation is announced for before the end of February 2027, and the April-May 2026 removal-and-restoration shows how quickly the ground moves ¹.

Injectable tier: FDA flags immunogenicity and impurity risk with limited human data ²; independent testing of consumer vials found high failure rates and endotoxin contamination ¹¹. Nothing about a vial labeled research use only is quality-assured for human injection.

No pregnancy or lactation data exists for any GHK-Cu product in any tier: no label, no registry, no study. The honest statement is that safety in pregnancy and breastfeeding is uncharacterized ⁵¹.

No interaction studies exist for GHK-Cu products ⁵¹. The popular claim that vitamin C inactivates copper peptides in a routine has no published clinical test we could locate; what is documented is chemistry-level, that GHK's activity in some assays tracks its copper delivery ¹⁵. We list no interaction rules because none have been established.

Cosmetics have no dose. What can be stated honestly is quantity arithmetic: dermatology's fingertip unit conventions put a face-and-neck application at about 2.5 FTU ⁴⁹, and the rule of hand makes one FTU about 0.5 g ⁵⁰. Our application-quantity guide uses only those published conventions to translate routines into grams and product lifespan, and it makes no efficacy claim at any quantity ^49,50.

Skin-penetration data are in vitro and disagree by method. Under 48-hour infinite-dose conditions on isolated human skin, copper from a 0.68% copper tripeptide solution permeated with a coefficient of 2.43 x 10^-4 cm/h and left a measurable skin depot ^37,38. In a 9-hour intact-skin experiment, almost nothing permeated without microneedle pretreatment ³⁹. A liposome-membrane model showed complex-dependent copper transport ⁴⁰. The 2025 methods review concludes the permeability information is insufficient ⁴⁶.

Endogenous plasma GHK is real and measurable: 133.0 ng/mL in healthy older adults and 70.27 ng/mL in COPD patients in the one recent study ³⁴; the traditional 200-to-80 age-decline figures come from the originating lineage ⁴⁵.

Human PK of the products people actually buy: absent. No study measures blood levels after a serum, a compounded cream or an injected vial ⁵³.

From a serum: pleasant cosmetics, a safety record that is genuinely reassuring at surveyed concentrations, and effects on wrinkles or firmness that no indexed randomized monotherapy trial has ever measured ^10,52. The one objective randomized test of GHK-Cu products on skin outcomes found nothing the instruments could see, while users still liked the result ²⁵.

From a compounded non-injectable product: the same evidence base as the serum, under an interim legal status that could change by early 2027 ¹.

From a vial: exposure to an FDA-flagged impurity risk in exchange for effects demonstrated in rodents and a worm ^2,36.

The FAQ below renders from the same claim ledger as everything else; each answer carries inline citations and a machine-readable 320-character summary.

Numbered references with resolving links follow; the citation manifest ships alongside this page as JSON.